Apolipoprotein E genotype moderates the association between dietary polyunsaturated fat and brain function: an exploration of cerebral glutamate and cognitive performance. (1st September 2020)

• Record Type: Journal Article
• Authors: Oleson, Stephanie; Eagan, Danielle; Kaur, Sonya; Hertzing, William J.; Alkatan, Mohammed; Davis, Jaimie N.; Tanaka, Hirofumi; Haley, Andreana P.
• Is Part Of: Nutritional neuroscience. Volume 23:Number 9(2020)
• Page Start: 696
• Page End: 705
• Publication Date: 2020-09-01
• Subjects: Apolipoprotein E -- Polyunsaturated fat -- Diet -- Proton magnetic resonance spectroscopy -- Memory -- Aging -- Alzheimer's disease; Neuropharmacology -- Periodicals; Diet -- Periodicals; Diet therapy -- Periodicals; Nutrition -- Periodicals; 615.78
• DOI: 10.1080/1028415X.2018.1547857
• Languages: English
• ISSNs: 1028-415X

Abstract

Abstract : Objective: To investigate the effect of Apolipoprotein E (APOE) genotype on the association between dietary polyunsaturated fat (PUFA), cognitive function, and cerebral glutamate. Methods: A participant sample of 122 middle-aged adults were grouped according to APOE genotype (ϵ4 carrier or ϵ4 non-carrier) and asked to record dietary intake for three consecutive days. All participants also underwent neuropsychological testing and a proton magnetic resonance spectroscopy ( 1 H MRS) scan to assess glutamate in the posterior cingulate cortex. Results: Multiple regression analyses revealed a significant interaction between APOE genotype and PUFA intake on memory performance, F (1, 113) = 6.749, p = .016. Greater PUFA intake was associated with better memory performance in healthy middle-aged adults who were APOE ϵ4 non-carriers, but not for ϵ4 carriers. Furthermore, there was a significant interaction between APOE genotype and PUFA intake on cerebral glutamate, in that dietary PUFA was associated with greater cerebral glutamate in APOE ϵ4 carriers, but not for ϵ4 non-carriers, F (1, 114) = 5.173, p = .025. Conclusions: The findings suggest that PUFA action on the brain differs according to APOE polymorphism and points towards cerebral glutamate as a potential marker of genetic risk for Alzheimer's disease (AD). Early treatment consisting of PUFA supplementation that is tailored to APOE genotype may be an important intervention for the prevention of cognitive decline.